Orthofix (OFIX) AI Stock Analysis

• Market Cap: $615.77M
• Dividend Yield: N/A
• Average Volume (3M): 236.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: 4.31%
• EPS Growth: 3.26%
• Country: US
• Employees: 1,616
• Sector: N/A
• Sector Strength: N/A
• Industry: Medical - Devices
• EPS (TTM): -0.57
• Shares Outstanding: 39,599,660
• 10 Day Avg. Volume: 187,608
• 30 Day Avg. Volume: 236,546
• PEG Ratio: 0.27
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 0.83
• P/FCF Ratio: -73.28
• Enterprise Value/Market Cap: 1.17
• Enterprise Value/Revenue: 0.88
• Enterprise Value/Gross Profit: 1.29
• Enterprise Value/Ebitda: 136.91
• 1Y Price Target: $20.00
• Price Target Upside: 33.24% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $16.00 ▲(6.60% Upside)

Orthofix's overall stock score is driven by mixed financial performance, with strong revenue growth but challenges in profitability and cash flow. Technical indicators are positive, supporting a favorable trend. The earnings call highlighted operational efficiency and growth, but valuation remains a concern due to ongoing losses.

Orthofix Business Overview & Revenue Model

Company Description

Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

How the Company Makes Money

Orthofix generates revenue through the sale of its medical devices and related services in the orthopedic and spine markets. Key revenue streams include the sale of bone growth stimulators, spinal implants, and orthopedic trauma products. The company also earns income from leasing and servicing its devices. Orthofix benefits from strategic partnerships with healthcare providers and distribution networks, which help in expanding its market reach. Additionally, the company invests in research and development to innovate and enhance its product offerings, which can lead to increased sales and market share.

Orthofix Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Orthofix Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 15.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OFIX, the sentiment is Neutral. The current price of 15.01 is below the 20-day moving average (MA) of 15.57, below the 50-day MA of 15.33, and above the 200-day MA of 13.83, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 50.52 is Neutral, neither overbought nor oversold. The STOCH value of 27.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OFIX.

Orthofix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
BVS	64 Neutral	$622.38M	69.10	4.97%	―	1.58%	―
SIBN	58 Neutral	$842.66M	-37.45	-12.91%	―	23.27%	43.90%
OFIX	55 Neutral	$615.77M	-5.09	-24.60%	―	4.31%	3.26%
AVNS	52 Neutral	$539.39M	-1.15	-46.68%	―	2.70%	-3090.51%
KIDS	52 Neutral	$449.13M	-8.86	-12.67%	―	19.90%	-57.90%
ZIMV	48 Neutral	―	―	-4.76%	―	-19.52%	94.65%

Orthofix Corporate Events

Orthofix Reports Q3 2025 Financial Results

Orthofix reported its financial results for the third quarter of 2025, showing a net sales increase of 5% on a reported basis and 6% on a pro forma constant currency basis compared to the same period in 2024. Despite a net loss of $22.8 million, the company achieved a positive free cash flow of $2.5 million and expanded its adjusted EBITDA margin for the seventh consecutive quarter. The U.S. Spine Fixation segment saw an 8% growth in net sales, driven by the 7D FLASH navigation technology, while the U.S. Orthopedics business benefited from the commercial launch of TrueLok Elevate. Orthofix has narrowed its full-year 2025 net sales guidance while raising the low end of its adjusted EBITDA guidance, indicating a strong operational performance and a commitment to long-term growth.